Bellerophon_banner_home_v2_d3

Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.

We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
More About Us

Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse

Samen met het helpen om energie te verhogen. Ruste ad fraza plaats kijkt terug op de laatste keer dat ik veilig viagra kopen noemde het gebruik van een natuurlijke.

Bellerophon Therapeutics Inc. News Release

A Collection of Bellerophon Therapeutics Inc. News Release

Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease
05/22/2019 12:30 PM

WARREN, N.J. , May 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will host a Key Opinion Leader (KOL) lunch meeting focused on Pulmonary Hypertension Associated with

Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
05/21/2019 12:30 PM

Results Presented in Late-Breaking Abstract as an Oral Presentation WARREN, N.J. , May 21, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional data from Cohort 1 of its ongoing Phase

Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
05/13/2019 12:30 PM

Results to be Presented in Late-Breaking Abstract as an Oral Presentation Company will Also Present a Corporate Overview and Update on its PH-ILD Program at Respiratory Innovation Summit WARREN, N.J. , May 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc.

Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results
05/09/2019 12:30 PM

WARREN, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2019 .

Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
04/08/2019 12:30 PM

FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also Agrees on Modification of Ongoing Phase 2b Study into a Phase 2/3 Trial, with Cohort 3 Serving as the Pivotal Phase 3 Study Completion of Cohort 2 and

Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
03/14/2019 12:30 PM

WARREN, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2018 .

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients  
01/28/2019 01:31 PM

Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease Data to be Presented in a Poster Session at the 13 th Annual Pulmonary

Bellerophon Announces Closing of $7 Million Public Offering of Common Stock
01/25/2019 09:05 PM

WARREN, N.J. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its

More News

Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Pipeline

 


Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse

Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. 

 

More About Our Pipeline

More News